EP2167497A2 — Heterocyclic compounds useful as raf kinase inhibitors

USPTO Abstract

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Cy1 is an optionally substituted phenyl or an optionally substituted 5-6 membered saturated, partially unsaturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Cy2 is an optionally substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur; L1 is a direct bond of an optionally substituted, straight or branched C1-6 alkylene chain; L2 is a direct bond, or is an optionally substituted, straight or branched C1-6 alkylene chain wherein 1 or 2 methylene units of L2 are optionally and independently replaced by -O-, -S-, -N(R)-, -C(O)-, -C(O)N(R)-, -N(R)C(O)N(R)-, -N(R)C(O)-, -N(R)C(O)O-, -OC(O)N(R)-, -SO2-, -SO2N(R)-, -N(R)SO2-, -OC(O)-, -C(O)O-, or a 3-6 membered cycloalkylene; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group;